

Continuing Innovations for the next 100 years **HOSOKAWA** MICRON CORPORATION



Poly-(Lactide-co-Glycolide) Acid



Drug Delivery System



> Safety

- > Functionality
- Productivity

Biocompatible, Bioabsobable

Increasing drug absorption, Sustained-release, Endocytosis, Drug protection

GLP/GMP manufacturing

> Diversity

Sterilization

Solid preparation (DPI, tablet etc.), Injection, Suspension, Coating layer

Filter sterilization for injectable formulation

Our Strength

Wide experience (low molecule ~ nucleic acid, peptide and protein)

- \succ High drug encapsulation (from <2% to over 20%)
- \succ Particle size control (form 50nm to 100 μ m)
- Powder processing (DPI, Tablet, Capsule)
- \succ Unique application (Coating onto balloon, stent)

> Mass production (over 100L scale/batch)

CGMP (Injection etc)

Would you like to develop a DDS preparation

or medical device using our PLGA

nanoparticle technology?



DDS performance of PLGA nanoparticle

Transdermal "Enhancement effect of drug skin permeability using PLGA nanoparicle"



Human skin tissue (35-year-old female, the armpit biopsy) By Laboratory of Prof. Miwa of Prefectural University of Hiroshima



Pulmonary



Dose of insulin: 3.0 IU/rat (n=6), significantly differently from control group (**p* < 0.05, ***p* < 0.01, ****p* < 0.001, student-t test)

Medical Device

"Development of drug eluting balloon catheter or stent using

Human skin tissue (52-year-old female, the upper eyelid biopsy) By Laboratory of Prof. Miwa of Prefectural University of Hiroshima

Oral nucleic acid delivery

"Suppression of active disease index of model rat(Inflammatory bowel disease) by orally administered NF-kB decoy PLGA nanoparticle"



Tahara K, et al. Biomaterials, 1-9 (2010)





Bioabsorbable DDS sheet

"Improvement of survival effect of rat model (liver cancer) administered DDS sheet containing anticancer drug loaded PLGA nanoparticle"

CRON HOROTANA MICHON		
AWA MICRON HOSOKAWA MICRON WA MICRON HOSOKAWA MICRON HOSOKAWA WA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA HOSOKAWA MICRON HOSOKAWA HOSOKAWA MICRON HOSOKAWA HOSOKAWA MICRON HOSOKAWA HOSOKAWA MICRON HOSOKAWA HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON	Insoluble outer layer	Soluble inner layer
VAMICRON HOSOKAWA MICRON HOSOKA KAWA MICRON HOSOKAWA MICRON HOS SOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON HOSOKAWA MICRON	Administered Samples (dose of anti-cancer drug A)	Improvement of Survival Rate ¹⁾
Frozen tissue section (24hrs after administration)	Drug solution administered by i.p (50µg) n=13	×
Tissue side	Attached sheet containing drug (8.75µg) n=12	×
	Attached sheet containing drug (27.1µg) n=12	O (power of DDS sheet)
	Attached sheet containing drug loaded PLGA nanoparticles (8.0µg) n=12	(power of PLGA nanoparticles

Attached Intraperitoneal DDS sheet contained Administration of PLGA with PLGA nanoparitcles nanoparicles suspension Data from Prof. Yamamoto of Aichi Gakuin Univ

HOSOKAW.

1) Significant difference v.s. control (saline solution administered by i.p., n=13); α <0.01, Mann-Whitney test, 60 days (max) after administration

